Interestingly, studies examining survival of T-SCLC derived from EGFR-mutant vs. EGFR wild type NSCLC have demonstrated differing outcomes, with one study showing reduced survival in the EGFR wild type group (6 vs. 10 months) [9], while the second study found no difference (9 vs. 10 months) [10]. Here, EGFR is linked to non-small cell lung carcinoma.